key: cord-0809634-53xret5p
authors: Clercq, Erik De
title: Highlights in Antiviral Drug Research: Antivirals at the Horizon
date: 2012-05-02
journal: Med Res Rev
DOI: 10.1002/med.21256
sha: 09477e8262fbfe90efeca2a040de4e9aa30b7b2b
doc_id: 809634
cord_uid: 53xret5p

This review highlights ten “hot topics” in current antiviral research: (i) new nucleoside derivatives (i.e., PSI‐352938) showing high potential as a direct antiviral against hepatitis C virus (HCV); (ii) cyclopropavir, which should be further pursued for treatment of human cytomegalovirus (HCMV) infections; (iii) North‐methanocarbathymidine (N‐MCT), with a N‐locked conformation, showing promising activity against both α‐ and γ‐herpesviruses; (iv) CMX001, an orally bioavailable prodrug of cidofovir with broad‐spectrum activity against DNA viruses, including polyoma, adeno, herpes, and pox; (v) favipiravir, which is primarily pursued for the treatment of influenza virus infections, but also inhibits the replication of other RNA viruses, particularly (‐)RNA viruses such as arena, bunya, and hanta; (vi) newly emerging antiarenaviral compounds which should be more effective (and less toxic) than the ubiquitously used ribavirin; (vii) antipicornavirus agents in clinical development (pleconaril, BTA‐798, and V‐073); (viii) natural products receiving increased attention as potential antiviral drugs; (ix) antivirals such as U0126 targeted at specific cellular kinase pathways [i.e., mitogen extracellular kinase (MEK)], showing activity against influenza and other viruses; and (x) two structurally unrelated compounds (i.e., LJ‐001 and dUY11) with broad‐spectrum activity against virtually all enveloped RNA and DNA viruses. © 2012 Wiley Periodicals, Inc. Med. Res. Rev., 00, No. 0, 1–34, 2012

The search for new antivirals has proceeded unabatedly. In previous reviews on "stories on antiviral drug discovery," I have reviewed various subjects in which I was personally involved. [1] [2] [3] [4] [5] In this review, hopefully the first of a new series, I will address "hot topics" in areas of antiviral research in which over the past few years significant progress has been made requiring due attention. Most of the compounds covered are still in the preclinical stage. Compounds that have successfully completed phase II and III clinical trials and progressing to approval (or have already been approved) are not subject of this review. Instead, this article is based on compounds in the pipeline that offer attractive perspectives as future antiviral drugs. In this sense, the present survey is a little arbitrary in the selection of the topics, which depends at least in part on my own prejudices and a number of other factors, not at least my own acquaintance with the subject.

An important impetus for initiating this review was based on the 24th ICAR Abstract Issue (Antiviral Research, vol. 90: A21-A78, 2011) covering the presentations at the 24th ICAR (International Conference on Antiviral Research), held in Sofia (Bulgaria) on May 8-11, 2011 . Unfortunately, I could not attend the Conference, but guided by a certain devotion, I went through the Abstract Issue and spotted a number of interesting leads which I would like to reflect on in the present article: (i) nucleoside analogues, targeted at hepatitis C virus (HCV) NS5B RNA polymerase, such as PSI-352938; 6 (ii) cyclopropavir for the treatment of human cytomegalovirus (HCMV) infections; 7 (iii) North-methanocarbathymidine (N-MCT) for the treatment of α-herpesvirus [herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2)] and γherpesvirus [Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) infection]; 8 (iv) CMX001 (1-O-hexadecyloxypropyl cidofovir) for the treatment of a broad variety of DNA virus infections; 9 (v) favipiravir (T-705) for the treatment of influenza virus infections and various other RNA virus infections; 10 (vi) the increasing number of compounds found effective against arenaviruses; 10, 11 (vii) new picornavirus (i.e., rhinovirus) inhibitors; 12, 13 (viii) natural products with antiviral activity such as aglycoristocetin derivatives 14 and tricin (4 ,5,7trihydroxy-3 ,5 -dimethoxyflavone); 15 (ix) mitogen extracellular kinase (MEK) inhibitors, such as U0126, acting at a cellular target, and effective against influenza and other viruses; 16 and (x) two unique sets of compounds which should be effective against virtually all enveloped DNA and RNA viruses. 17 Taken together, compounds (i) through (x) cover all major viral pathogens: polyoma-, adeno-, herpes-, pox-, picorna-, flavi-, arena-, myxo-, bunya-, and retroviruses, and particularly HSV, HCMV, hemorrhagic fever, influenza, and human immunodeficiency virus (HIV).

2 -Deoxy-2 -fluorocytidine (FdC) could be considered as the first nucleoside analogue ( Fig. 1) found to inhibit the hepatitis C virus (HCV) replicon in cell culture, its 5 -triphosphate inhibiting the NS5B polymerase. 18 Introduction of a methyl group at the C-2 position, as in β-D-2 -fluoro-2 -C-methylcytidine ( Fig. 1) , conferred a similar potency as FdC in the HCV replicon assay. 19 Although the 2 -C-methylcytidine (Fig. 1 ) demonstrated somewhat lesser activity against HCV than 2 -deoxy-2 -fluoro-2 -C-methylcytidine, 19 the prodrug of 2 -C-methylcytidine, its 3 -Ovaline ester, NM283 (valopicitabine) (Fig. 1 ) was developed (but later dropped) for phase II clinical trials. 20 Introduction of a 4 -azido group (Fig. 1) , as in R1479, 21, 22 RO-9187, RO-0622, 23 4 -azido-2 -deoxy-2 ,2 -difluorocytidine, and 4 -azido-2 -deoxy-2 -fluoroarabinocytidine significantly increased the potency in the HCV replicon system [i.e., with 50% effective concentration (EC 50 ) values of 66 and 24 nM for the latter two compounds]. 24 The 2 ,3 ,5 -triisobutyrate ester prodrug of 4 -azido-2 -C-methylcytidine (RG1626) (Fig. 1 ) has been (but is no longer) in development as inhibitor of HCV, according to Reddy et al. 25 According to Reddy et al., 25 RG7128 ( Fig. 1) is currently in phase IIb clinical trials. RG7128 is the 3 ,5 -diisobutyrate ester prodrug of PSI-6130 (Fig. 1) ; in a 4-week combination study with the current standard of care (soc) for HCV infection (i.e., combination of pegylated interferon-α and ribavirin), RG7128 demonstrated efficacy in genotype 1, 2, and 3 patients, and, therefore, represents the first direct acting antiviral to show pan-genotype HCV coverage in the clinic. PSI-6130 (β-D-2 -deoxy-2 -fluoro-2 -C-methylcytidine) is a potent inhibitor of HCV replication in the HCV replicon system [for an efficient, diastereoselective synthesis of PSI-6130, see Wang et al. 26 ]. To be active at the NS5B RNA polymerase level, PSI-6130 must be phosphorylated successively to its 5-mono-, di-, and triphosphate, the final, active metabolite which acts as a chain terminator of the NS5B RNA polymerase. 27 However, in addition to the 5 -triphosphate of PSI-6130, the 5 -triphosphate of its uridine counterpart, β-D-2 -deoxy-2fluoro-2 -C-methyluridine (RO2433) (Fig. 1) , is also formed, 28 and this second metabolite of PSI-6130 is also a potent inhibitor of the HSV NS5B RNA polymerase. 29 Deamination of PSI-6130 occurs at the 5 -monophosphate level. 29 RO2433 (Fig. 1) itself is inactive in the HCV replicon system, but its phosphoramidate prodrug PSI-7672 ( Fig. 1) is active in this system, where it is released as its 5 -monophosphate which can then be further phosphorylated intracellularly to the 5 -di-and 5 -triphosphate. 29 From R02433 (a uridine homolog, which was renamed PSI-6206), another phosphoramidate prodrug, PSI-7851 ( Fig. 1) was prepared, which proved to be pan-genotype inhibitor of HCV replication, with, however, lesser activity against the S282T replicon mutant (while the S96T/N142T mutation remained fully susceptible to PSI-7851). 30 Inside the cell, PSI-7851 is converted to the 5 -monophosphate of PSI-6206, and in this sense, PSI-7851 can be considered as a prodrug of PSI-7411. 31 PSI-7851 is, in fact, a mixture of two diastereoisomers, PSI-7976 (Rp diastereomer) and PSI-7977 (Sp diastereomer), the latter being the more active inhibitor of HCV RNA replication in the replicon system. 31, 32 PSI-7977 is currently being evaluated in phase II clinical trials. 33 From 2 -deoxy-2 -fluoro-2 -C-methylguanosine-5 -monophosphate a phosphoramidate prodrug was prepared, PSI-353661 ( Fig. 1 ), which proved highly active against genotypes 1a, 1b, and 2a HCV RNA replication in the replicon system, genotype 1a and 2a infectious virus production, and HCV replicons harboring the NS5B S282T or S96T/N142T mutations. 33 

,5R)-5-(2-amino-6-methoxy-purin-9-yl)-4-(R)-fluoro-3-hydroxy-4methyl-tetrahydro-furan-2-yl-methoxy]-phenoxy-phosphonylamino}-propionic acid isopropyl ester] is the more active isomer of a mixture (PSI-352879) of two diastereoisomers.

Recently, the 2 -deoxy-2 -α-fluoro-2 -β-C-methyl 3 ,5 -cyclic phosphate prodrug PSI-352938 ( Fig. 1 ) was described. Based on its antipan-genotype HCV activity (EC 50 for the replicons in the 0.1-0.2 μM range) also including activity against S282T or S96T/N142T mutations, ability to produce high intracellular 5 -triphosphate levels both in vitro and in vivo, the synthetic accessibility of a single diastereomer, 34 PSI-352938 was selected for further development. 25, 35 The compound is currently in phase I clinical trials.

Supportive of continued development as a clinical candidate for the treatment of HCV infection is INX-08189 or (2S)-neopentyl 2-(2R,3R,4R)-5-(2-amino-6-methoxy-9H-purin-9-yl)-3,4dihydroxy-4-methyltetrahydrofuran-2-yl)(methoxy)(naphthalen-1-yloxy)(phosphorylamino) propanoate, an aryl-phosphoramidate of 6-O-methyl-2 -C-methyl guanosine; its EC 50 for 1a, 1b, and 2a HCV replicons is around 0.01 μM. 36 The separated diastereomers of INX-08189 were shown to have similar activity in the replicon assay. INX-08189 has completed investigational new drug (IND) enabling studies and has progressed to human clinical trials for the treatment of chronic HCV infection. 37 

Cyclopropavir (Fig. 2) can be viewed as structurally related to acyclovir, ganciclovir, and penciclovir in that the acyclic side chain of the latter has been replaced by a methylenecyclopropane. Its antiviral properties have been known since a decade or so. 38 Cyclopropavir has proven to be effective against herpesviruses. 39, 40 It has proven particularly effective in animal models for cytomegalovirus (CMV) infection, 41 including SCID-hu (where SCID is severe combined immunodeficient) mouse models for HCMV. 42 In addition, cyclopropavir has also been found effective in vitro against human herpesvirus type 6 (HHV-6), like HCMV, a β-herpesvirus. 43 Currently available drugs for the treatment of HCMV infections are ganciclovir, cidofovir, foscarnet, and valganciclovir (the valine ester of ganciclovir). Esterification of ganciclovir with L-valine increased its oral bioavailability, as was previously also shown for acyclovir (valaciclovir) and would be later shown for the valine esters of 2 -deoxy-L-cytidine (valtorcitabine) and 2 -C-methylcytidine (valopicitabine). 20 Also, the L-valine ester of cyclopropavir (valcyclopropavir) (Fig. 2) has been constructed. 44 In mice, oral bioavailability of valcyclopropavir was 95%.

Against all those HCMV strains against which cyclopropavir was compared with ganciclovir, cyclopropavir displayed an EC 50 that was five-to tenfold lower than that of ganciclovir. 45 This was also the case for UL97 mutations that affected cyclopropavir and ganciclovir susceptibility. In fact, purified pUL97 phosphorylated cyclopropavir (to its monophosphate) 45-fold more extensively than ganciclovir. 46 This phosphorylation is stereoselective.

Cyclopropavir monophosphate is converted successively to its diphosphate and its triphosphate (the latter is the active metabolite interacting with the HCMV pUL54 DNA polymerase) by a single cellular enzyme, guanosine monophosphate kinase (GMPK), once the monophosphate is formed by a virally encoded kinase. 47 While new and safe anti-HCMV drugs are eagerly awaited, the fact that cyclopropavir has excellent activity against HCMV, combined with its specific phosphorylation by the viral enzyme pUL97 would seem to justify further development of the compound and its valine ester (valcyclopropavir), and eventually that of its phosphonate and cyclic phosphonate as well. 48 It is curious, in this regard, that while both the phosphonate and cyclic phosphonate (Fig. 2) were equally active against HCMV, only the phosphonate, but not the cyclic phosphonate, was active against the γ -herpesvirus, EBV. 48 

N-methanocarbathymidine (N-MCT) with a pseudosugar rigidly fixed in the Northern confor- Fig. 3 ) was first synthesized by Marquez et al. in 1996. 49 It was found to exhibit potent antiviral activity against HSV-1 and HSV-2. This was further corroborated in subsequent studies. 50-52 N-MCT appeared to be phosphorylated to the mono-and diphosphate by the HSV-encoded thymidine kinase, and to inhibit the viral DNA polymerase through its triphosphate metabolite. 50 Kinases would prefer substrates that adopt the S sugar conformation, whereas cellular DNA polymerases almost exclusively incorporated the triphosphate of the locked N conformer, notwithstanding the presence of higher triphosphate levels of the S-conformer S-MCT ( r DE CLERCQ Antiviral activity against vaccinia virus was first shown with carbocyclic thymidine (Fig. 3 ). 54 N-MCT was found to be highly effective against orthopoxvirus infections in vivo (mice), 55, 56 although the lung, nasal, brain virus reductions it achieved for vaccinia virus infection (1HD strain) were not nearly to the same extent as for cidofovir. 57 Vaccinia virus lacking the F2L gene encoding functional deoxyuridine triphosphatase (dUTPase, that catalyzes the conversion of dUTP to dUMP) continued to replicate well in vitro and in vivo, but proved hypersensitive to the inhibitory effect of N-MCT. 58 As to its activity spectrum, N-MCT is not only active against the α-herpesviruses HSV-1, HSV-2, but also against the γ -herpesviruses EBV 55 and KSHV. 59 Apparently, N-MCT inhibits lytic KSHV DNA synthesis through its triphosphate metabolite produced in KSHV-infected cells expressing a virally encoded thymidine kinase. 59 Recently, a "greener" enantioselective synthesis of N-MCT from 2-deoxy-D-ribose has been reported 60 and a new MCT distinct from N-MCT, namely D-(+)-iso-MCT (Fig. 3) , has been described as a high-affinity substrate for HSV-1 thymidine kinase. 61 N-MCT shows potent anti-HIV activity in human osteosarcoma (HOS) cells modified so as to contain, and express, the HSV-1-encoded thymidine kinase. Possible anti-HIV activity of D-(+)-iso-MCT may have been masked by cytotoxicity. 61 N-MCT represents an interesting conformational concept. 62 Its therapeutic utility, however, remains to be demonstrated. As there are, at present, no therapeutic options for EBV and KSHV infections, these infections may well represent unique opportunities for the clinical potential of N-MCT to be further explored.

CMX001 is the 1-O-hexadecyloxypropyl (HDP) prodrug of the acyclic nucleoside phosphonate cidofovir (CDV), representing an oral version of cidofovir with reduced (nephro)toxicity. 63 The active form of HDP-CDV (CMX001) is cidofovir (Fig. 4) , which explains why, in principle, CMX001 should possess an activity spectrum similar to that of cidofovir, thus, encompassing DNA viruses, herpes-, adeno-, polyoma-, and poxviruses. For all these indications, CMX001 could, given its oral bioavailability and safer (nephro)toxicity profile, replace cidofovir in future therapeutic regimens.

Against disseminated or central nervous system (CNS) HSV infections, firm Chimerix (CMX) appears to be superior to acyclovir. 64 Orally administered HDP-CDV is four-to eightfold more active, on a molar basis, than intraperitoneally administered cidofovir against HCMV infection in SCID/hu mice. 65 HDP-cidofovir exhibits multiple-log enhancement of antiviral activity against both HCMV and HSV replication in vitro, 66 and oral treatment with HDP-CDV is as effective as parenteral CDV for the treatment of murine CMV infections. 67 As long awaited, oral HDP-CDV improves the outcome of CMV infection in a congenital model for CMV infection in pregnant guinea pigs. 68 Ether lipid esters of cidofovir, such as HDP-CDV, are much more potent than cidofovir against adenovirus replication in vitro. 69 HDP-CDV (CMX001) suppressed adenovirus-induced mortality in immunosuppressed hamsters, a powerful model to evaluate the efficacy of antiadenovirus agents. 70 A first case of the successful eradication of disseminated adenovirus infection by CMX001 has been recently reported in a severely immunosuppressed pediatric stem cell transplant recipient. 71 In line of earlier observations on the inhibitory effects of cidofovir against murine and primate polyomaviruses, 72 cidofovir was shown to inhibit polyomavirus BK replication in human renal tubular cells. 73 Either lipid esters of cidofor such as HDP-CDV were then shown to inhibit polyomavirus BK replication in vitro at a 3 log 10 -fold lower concentration than cidofovir. 74 CMX001 proved highly effective in inhibiting polyomavirus BK replication in primary human renal tubular epithelial cells. 75 This points to the potential of CMX001 in the treatment of BK virus nephropathy that is seen in 1-10% of kidney transplant recipients.

The JC polyomavirus infects human oligodendrocytes leading to the development of progressive multifocal leukoencephalopathy. CMX001 was shown to suppress polyomavirus JC in human fetal brain SVG cell cultures 76 [the SVG cell line is derived from primary human brain cells transfected with Simian virus 40 (SV40) and expressing SV40 T antigen in these cells]. CMX001 was recently shown to inhibit polyomavirus JC replication in human brain progenitor-derived astrocytes, 77 and a case of progressive multifocal leukoencephalopathy (accompanied by idiopathic CD4 + lymphocytopenia) responded successfully to treatment with CMX001. 78 Alkoxyalkyl esters of cidofovir, including HDP-CDV, have been most intensively pursued for inhibition of orthopoxvirus replication. 79 They were first proven active in vitro against vaccinia virus and cowpox, 80 before their in vivo activity against the same viruses was demonstrated. 81 Their efficacy was demonstrated in a lethal mousepox model (based on lethal, aerosol ectromelia virus infection in A/NCR mice). 82 In an improved model for evaluating antipoxvirus therapies, based on the use of C57BL/6 mice infected with mousepox (ectromelia) virus, CMX001 proved more efficacious than in A/NCR mice. 83 Ectromelia virus infection of mice serves as a model to support the licensure of antiorthopoxvirus therapeutics based on the "animal efficacy rule" because of the genetic similarity of ectromelia virus to variola and monkeypox viruses. 84 In the lethal mousepox model, complete protection against mortality was achieved when administration of CMX001 was delayed until as late as 5 days postinfection. 85 A single dose of 25 mg/kg of CMX001 administered 4 or 5 days postinfection sufficed to be effective in the mousepox model. 86 CMX001 is also efficacious in the treatment of monkeypox virus infection in STATIdeficient C57BL/6 mice. 87 Against the highly virulent, interleukin-4 expressing ectromelia virus recombinant, CMX001 may afford the highest efficacy when combined with another antiviral drug, ST-246. 88 The pre-and postexposure prophylactic efficacy of CMX001 has also been demonstrated in rabbits infected with rabbitpox virus. 89, 90 Compared with CDV, CMX001 would have the advantages that it could be administered orally (whereas CDV needs to be administered intravenously) and, unlike CDV, CMX001 may not lead to nephrotoxicity. 91 

Favipiravir (T-705) (Fig. 5) is currently in clinical trials in Japan (phase III) and the United States (phase II) for the treatment of influenza virus infections (as mentioned by Buys et al. 94 ). The in vitro and in vivo activities of T-705 (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) were first reported in 2002 by Furuta et al. 95 The compound showed potent inhibitory activity against influenza A, B, and C viruses, some activity against picorna-and paramyxoviruses, but no activity whatsoever against DNA viruses. From its structure, it was immediately clear that the mode of action of T-705 had to be different from that of the M2 ion channel inhibitors amantadine and rimantadine, as well as that of the neuraminidase inhibitors zanamivir and oseltamivir. This mechanism of action was further addressed by Furuta et al. 96 Within the cells, T-705 would be converted to T-705 ribofuranosyl monophosphate by a purine (adenine, hypoxanthine/guanine) phosphoribosyl transferase. Two phosphorylations would then generate T-705-4-ribofuranosyl-5 -triphosphate (T-705 RTP), the active metabolite of T-705. 96 That the latter is indeed the active metabolite of T-705 was also shown in cells infected with the highly pathogenic influenza A (H5N1) virus. 97, 98 Meanwhile, Sidwell et al. 99 had shown that T-705, when orally administered at dosages from 30 to 300 mg/kg (once or twice daily), prevented death due to a lethal avian influenza A (H5N1) virus infection in mice. In vitro, favipiravir proved antivirally active against influenza A (H1N1) virus strains that were resistant to antiviral drugs such as oseltamivir, 100 and, in vivo, synergistic effects were obtained with favipiravir combined with oseltamivir against influenza A (H5N1) infection. 101 The carboxamide group present in favipiravir (T-705) is reminiscent of the carboxamide present in ribavirin. This carboxamide group is also present in T-1105 and T-1106, two compounds that are structurally related to T-705 (Fig. 5) . All the compounds share, with ribavirin, a broad-spectrum activity against various RNA viruses. Thus, T-1105 shows activity against foot-and-mouth disease virus (FMDV) and, as it can be administered through food, it could be a powerful tool to control foot-and-mouth disease in pigs. 102 T-1106 has proven efficacious against Yellow fever virus (YFV) in a hamster model of YFV infection 103 and is also active against bovine viral diarrhea virus (BVDV), 102 another flavivirus that could be considered as a surrogate virus for hepatitis C virus (HCV).

T-705 is also efficacious in the YFV hamster model, although the dose of T-705 required for efficacy in hamsters is higher than that of T-1106 required for efficacy. Yet, T-705 improved the disease parameters in YFV-infected hamsters, which may indicate its potential utility in the treatment of YFV infection in humans. 104 In rodents (mice or hamsters), orally administered T-705 is also effective against West Nile virus (WNV), 105 another flavivirus related to YFV. Whether T-705 or any of its analogues T-1105 or T-1106 would be effective against two other mosquito borne flaviviruses, dengue virus and Japanese encephalitis virus, remains an intriguing possibility worth exploring. Western equine encephalitis virus (WEEV), an alphavirus belonging to the broad family of the flaviviridae, would seem to respond to T-705 treatment. 106 The antiviral activity spectrum of T-705 extends to arenaviruses: that is, Junin virus (JUNV), Pichinde virus, Tacaribe virus, Machupovirus (MACV), and Guanarito virus (GTOV) replication in cell culture could be inhibited by T-705, and as previously noted for its inhibitory effect on influenza virus, the antiarenavirus activity of T-705 could be reversed by the addition of purine, but not pyrimidine nucleosides. 107, 108 T-705 also proved efficacious against Pichinde virus infection in hamsters, even when treatment was begun after the animals fell ill, the day before the animals began to succumb to the disease. 109 Thus, for the treatment of late stage arenaviral hemorrhagic fever, T-705 could be considered as an alternative option to ribavirin. This would seem very important for severe arenavirus infections, such as Lassa fever, in humans.

Besides arenavirus infections, bunyaviruses, that is, Punta Toro, La Crosse, Rift Valley fever, and sandfly fever virus, have also proven sensitive to inhibition by T-705 in vitro, and, for Punta Toro virus, also in vivo (mice and hamsters). 107 In hamsters infected with Punta Toro virus, T-1106 was more efficacious than T-705, but in mice, T-705 was the more effective. 110 Of the bunyaviridae, the hantaviruses Dobrava and Maporal were found to be sensitive to the inhibitory effects of T-705. 94 Maporal virus is phylogenetically similar to Andes virus, the principal cause of hantavirus cardiopulmonary syndrome (HCPS) in Argentina. It would now seem mandatory to further explore the efficacy of T-705 in the suitable hantavirus models in hamsters and/or mice.

In conclusion, T-705 is an intriguing new antiviral compound that should be further explored not only for its clinical potential in the prevention/therapy of influenza virus infections, but also for its broad activity spectrum against (−) and (+) RNA strand viruses, its target of action (RNA-dependent RNA polymerase for all these RNA viruses ?), and its structureactivity relationship and pharmacodynamics relative to that of related structural analogues such as T-1105 and T-1106.

Since McCormick's pioneering paper in 1986 111 on the effective therapy of Lassa fever with ribavirin, ribavirin has remained the only antiviral drug available for the treatment of arenavirus infections. The inhibitory effect of ribavirin on arenaviruses might, at least partially, be attributed to lethal mutagenesis. 112 In recent years, antiarenaviral drug development has received increasing attention, 113, 114 one of the new antiarenaviral drug candidates being favipiravir (T-705) (see preceding section).

The Tacaribe arenavirus infection model has been employed to explore the antiviral potential of novel aristeromycin analogues, 115 and new imidazo[2,1-b]thiazole carbohydrate derivatives have been found to inhibit the replication of the Argentine hemorrhagic fever virus Junin. 116 Small interfering (si)RNAs targeting the conserved RNA termini of Lassa fever virus 117 offer therapeutic potential and so do interferon-α and interferon-γ , 118 whereas antimicrobial cationic peptides were found active against JUNV as well as HSV-1 and HSV-2. 119 Lassa fever virus is restricted by the bone marrow stromal antigen 2 (BST-2), also called tetherin, which besides inhibiting the release of HIV-1, also inhibits the egress of arenaviruses. 120 Tetherin could thus be considered an innate immunity strategy to suppress arenavirus replication.

The Lassa fever viral nucleoprotein (NP) is endowed with several functions (i.e., a 3 -5 exoribonuclease a the C-domain, involved in suppressing interferon induction, and a m7GpppN cap-binding site at the N-domain, protecting the cap against cap snatching), which may serve as potential targets for chemotherapeutic intervention. 121 One of the most fascinating targets for novel antiarenavirus strategies is the arenavirus envelope glycoprotein complex (GPC) processing by the cellular site 1 protease (S1P), which is strictly required for the production of infectious progeny and cell-to-cell virus propagation. 122 The small molecule PF-429242 (Fig. 6 ) was recently reported to be a potent S1P inhibitor in vitro (cell-based assay). 123, 124 This correlated with the compound's potent antiviral activity against Lassa fever virus in cell culture. 125 Of the small molecular weight inhibitors targeted at arenaviral entry, in particular the viral glycoprotein GP2, the first to be announced chosen for drug development was ST-294 (Fig. 6) . 126 The arenavirus GP is synthesized as a single polypeptide that undergoes posttranslational processing to yield the mature virion glycoproteins GP1 and GP2. GP1 is involved in receptor binding, whereas GP2 is similar to the fusion proteins of other enveloped viruses such as retroviruses, paramyxoviruses, and filoviruses. A series of small molecules, including 17C8 (Fig. 6) have been identified to be targeted at the arenavirus GP. 127 These small molecule entry inhibitors (including ST-294 and interact with the envelope GPC of arenaviruses so as to stabilize the complex against pH-induced activation of membrane fusion in the endosome. 128 Both ST-294 and ST-193 (Fig. 6) inhibit the pHinduced dissociation of the receptor-binding GP1 subunit from GPC. ST-294 and ST-193 thus stabilize the GPC against pH-acidification which would otherwise initiate the fusion process. 129 The antiviral potency of ST-193 (Fig. 6) against Lassa virus and other arenavirus pseudotypes is within the range of 0.2-12 nM. The sensitivity to ST-193 is dictated by a segment of about 30 amino acids within the GP2 subunit. This region includes the carboxy-terminal region of the ectodomain of the transmembrane domain of the envelope protein. 130 The small molecule arenavirus inhibitor ST-193 was compared with ribavirin in a guinea pig model for Lassa virus infection, and found to increase the survival rate from 0% (control, ribavirin) to 62.5% .

What now remains to be established is how ST-193 compares with other arenavirus inhibitors such as favipiravir (T-705) and PF-429242, both in terms of efficacy and safety, and whether its efficacy can be extrapolated from Lassa to other arenavirus infections such as Junin, Machupo, Sabia, and Guanarito.

Although picornaviruses encompass a number of important human pathogens, including the enteroviruses polio, Coxsackie A and B, and echo, and rhinoviruses, there is still no single antipicornavirus agent approved for clinical use. Yet, a wealth of compounds has been shown to inhibit picornaviruses, including, especially for Coxsackie B virus, a number of natural products (see Section 8) . Prominent among the currently envisaged antipicornavirus therapies 131 are the original Winthrop compounds (disoxaril derivatives), which engage in a specific binding to the viral capsid.

Pleconaril (Fig. 7) , the prototype of this class of compounds, 132 had been shown to inhibit the replication of various entero-and rhinoviruses 133 and had demonstrated tentative efficacy against potentially life-threatening enterovirus infections, 134 before, in 2002, it was rejected by the US FDA for the treatment of common cold. 135 Several double-blind placebo-controlled trials with pleconaril in infants with enterovirus meningitis, 136 and adults with common cold 137 were conducted, and Pevear et al. 138 showed that the efficacy of pleconaril in reducing the duration and severity of common cold symptoms (when it was administered within 24 hr of symptom onset) was related to the virus susceptibility to pleconaril. De Palma et al. 139 in their review mentioned that a phase II double-blind, placebo-controlled trial to evaluate the effects of pleconaril nasal spray on common cold symptoms and asthma exacerbations following rhinovirus exposure was completed in 2007, but that results of this trial have not yet been divulged.

Pleconaril has in the meantime been found to shorten the course of illness, compared to placebo, in patients with enteroviral meningitis, but the benefit appeared to be modest after adjusting for confounding variables. 140 Pleconaril did not have any effect on viral replication in a common variable immunodeficiency (CVID) patient with parechovirus-associated Medicinal Research Reviews DOI 10.1002/med enteropathy. 141 New pleconaril derivatives have been reported to be active against pleconarilresistant Coxsackie B virus. 142 Meanwhile, new benzimidazole derivatives have been synthesized and found active against Coxsackie B3 virus, 143 and a small interfering (si)RNA has been shown to block Coxsackie B virus replication. 144 Synergistic activity against Coxsackie B3 virus was obtained if the siRNA was combined with the soluble Coxsackievirus-adenovirus receptor. 145 A new class of compounds, which be structurally described as 9-arylpurines, was recently described to inhibit a variety of enteroviruses, that is, Coxsackie A16, A21, A24, Coxsackie B3, and echovirus 9, at low micromolar concentrations. 146 In earlier papers dating from 2003 to 2004, we have demonstrated that Coxsackie B3 virus-induced myocarditis in mice can be inhibited by mycophenolate mofetil, 147 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile, 148 and the interferon inducer ampligen [poly(I).poly(C 12 ,U)]. 149 Three antipicornavirus agents are currently in clinical development: pleconaril, BTA-798, and V-073 150 (Fig. 7) . Pleconaril is under development as an oral formulation for the treatment of rhinovirus infections in high-risk patients with chronic lung diseases. 139, 151, 152 Oral BTA-798 is in phase II trial for symptomatic human rhinovirus infection in asthmatic adults. 139 V-073 is under further scrutiny for the treatment of poliovirus infections. Their EC 50 values are, respectively, for BTA-798 0.02 μM against human rhinovirus type 14 and 0.2 μM against enterovirus 71, 0.06 μM for pleconaril against human rhinovirus type 14, and 0.026 μM for V-073 against poliovirus type 1. 150 Pleconaril, BTA-798 and V-073 behave as capsid binders. They could, if required, be combined to provide an additive to slightly synergistic antiviral effect. 150 As reviewed recently, 153 antivirals directed against human rhinoviruses could be used to treat the common cold, but also be employed therapeutically or prophylactically to prevent asthma and chronic obstructive pulmonary disease (COPD) exacerbations in high-risk patients.

Natural compounds, primarily those originating from plants, have received increasing attention for their antiviral potential. Typical examples are constituents of Ardisia chimensis 154 and caffeoylquinic acids from Schefflera heptaphylla, 155 both originating from Southern China and found active particularly against Coxsackie B3 virus.

Norsesquiterpenoids isolated from the roots of Phyllanthus emblica showed, again, some activity against Coxsackie B3 virus 156 and triterpenoids isolated from S. heptaphylla (Fig. 8) were accredited with broader activity against Coxsackie B3, influenza A, respiratory syncytial virus (RSV), and HSV-1. 157 Calycosin-7-O-beta-D-glucopyranoside (Fig. 8) , the main isoflavonoid isolated from Astragalus membranaceus, also showed activity against Coxsackie B3 virus in vitro, and would improve the survival rate of mice infected with Coxsackie B3 virus. 158 Flavans 7-O-galloyltricetifavan and 7,4 -di-O-galloyltricetifavan isolated from the leaves of Pithecellobium clypearia would show activity against the same array of viruses (Coxsackie B3, influenza A, RSV, and HSV-1) as the triterpenoids mentioned above. 159 Homoisoflavonoids 3-benzyl-4-chromones (Fig. 8) showed activity against Coxsackie virus B1, B3, B4, A9, and echovirus 30, but not against poliovirus. 160 The flavone 4 ,5,7-trihydroxy-3 ,5 -dimethoxyflavone (tricin), isolated from the bamboo Sasa albo-marginata was found effective against HCMV at an EC 50 of 0.17 μg/mL which means a stronger antiviral activity than ganciclovir. 161 Tricin has also been accredited with antiinfluenza virus activity. 162 To increase the oral bioavailability of tricin, it has been conjugated with alanine-glutamic acid. The prodrug of tricin (tricin-alanine-glutamic acid) showed excellent oral bioavailability upon oral administration in rats. 163 The isoflavone genistein (Fig. 8 ) was originally isolated from fermentation broth of Pseudomonas sp. 164 and initially described as a tyrosine-specific protein kinase inhibitor. 165 Only recently, genistein has been shown to inhibit arenavirus infection, 166 putatively by inhibiting arenavirus entry which occurs through a cholesterol-dependent clathrin-mediated endocytic mechanism. 167 Raoulic acid (Fig. 8) is the principal ingredient of Raoulia australis. It was shown to inhibit picornaviruses, that is, rhinovirus 2 (HRV2), rhinovirus 3 (HRV3), Coxsackie B3, Coxsackie B4, and enterovirus 71 at EC 50 values in the range of 0.1-0.4 μg/mL, that is, at lower concentrations than those at which the aforementioned triterpenoids and flavans showed antiviral activity. 169 However, raoulic acid did not show activity against influenza A or B. 169 Terameprocol is a methylated derivative of nordihydroguaiaretic acid, a phenolic antioxidant extracted from the creosote bush Larrea tridentate. 170 Terameprocol (Fig. 8) has been found to inhibit the growth of poxviruses, that is, cowpox and vaccinia, by preventing the spread of virus particles from cell to cell. 170 Nigericin (also known as antibiotic K-178, helexin C, azalomycin M, antibiotic X-464, and polyetherin A) has also been shown to inhibit poxvirus replication. 171 It had been previously reported to inhibit poliovirus and influenza virus replication. 172, 173 Aglycoristocetin derivatives with a cyclobutenedione carrying hydrophobic chains such as methylene bis(phenylene) (Fig. 8) inhibit influenza A and B virus infections, probably by interference with the viral entry process. 174 These types of compounds (derivatives of glycopeptide antibiotics) have been previously shown to inhibit the replication of retroand coronaviruses and this inhibitory effect was also attributed to interference with virus entry. 175, 176 Brassinosteroids, that is (22S,23S)-3β-bromo-5α,22,23-trihydroxy stigmastan-6-one (Fig. 8) , represent naturally occurring polyhydroxy steroidal plant hormones modulating the growth and differentiation of plant cells. Their antiviral activity has been well documented. 177, 178 Brassinosteroids are particularly active against arenaviruses such as Tacaribe, Pichinde, and Junin. 179 Biyouyanagins A and B were originally obtained from Hypericum chinense and shown to be active against HIV. 180 These compounds possessing antiarenavirus and anti-HIV properties have been recently obtained by total synthesis, and their originally assigned structures were revised (Fig. 8) . 181 In conclusion, a wealth of natural products has been reported to possess antiviral properties. In the majority of these cases the chemical structure was well identified but the full antiviral activity spectrum of the compounds still needs to be evaluated, their mode of action elucidated, and, most importantly, their therapeutic value delineated.

U0126 (Fig. 9) is the prototype of the MEK (mitogen-activated protein/extracellular signalregulated kinase) inhibitors acting at the tiered serine/threonine kinase Raf/MEK/extracellular regulated kinase (ERK) signaling pathway, able to suppress the propagation of the pandemic H1N1 influenza virus and highly pathogenic avian influenza virus in vitro and in vivo. 182 Among the MEK inhibitors, PD 0325901 and PD 184352 (Fig. 9 ) have been used in clinical trials against cancer. 183, 184 They are also inhibitory to influenza virus infection in vitro. 182 MEK inhibitors such as U0126 not only reduce virus titers in vitro and in vivo, but also reduce proinflammatory cytokine expression. 185 MEK inhibitors, such as U0126, have also been shown to suppress influenza B virus propagation. 186 Most importantly, to date this happened without the emergence of any resistant virus variants, demonstrating that influenza viruses cannot easily adapt to interference with cellular functions.

Influenza virus infections require the induction of a variety of cytokines including those that are regulated by transcription factors of the activating protein-1 (AP-1) family and the NK (Jun-N-terminal kinase) pathway. 187 These different protein kinase pathways may ultimately lead to RANTES production in influenza virus-infected human bronchial epithelial cells. 188 The Raf/MEK/ERK cascade is the prototype of mitogen-activated protein (MAP) kinase cascades: inhibition of Raf-signaling results in nuclear retention of viral ribonucleoprotein complexes (RNPs), and concomitant inhibition of virus production. Signaling through the mitogenic cascade seems to be essential for influenza virus production. 189 The Raf, MEK, and ERK pathway not only plays an important role in the replication of influenza A and B virus, but also in the replication of HIV, 190, 191 Coxsackie virus B3, 192 coronavirus, 193 and HSV. 194 MEK inhibitors such as U0126 should therefore impair the propagation of these viruses, as has been specifically shown for U0126 against HSV-2 194 and X4 HIV-1. 191 The Raf/MEK/ERK signaling cascade is activated upon infection with Borna disease virus (BDV), a noncytolytic highly neurotropic single-stranded RNA virus, the only known member of the Bornaviridae (Mononegavirales) and, again, the MEK inhibitor U0126 was found to block spread of BDV in cultures cells. 195 The pathogenesis of hemorrhages in dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS) is poorly understood. The hemorrhages may be related to the induction of the plasminogen activator inhibitor type 1 (PAI-1) via activation of the MEK/ERK pathway, the MEK inhibitor U0126 almost completely suppressed PAI-1 expression, 196 and may therefore be assumed to suppress hemorrhages in DHF/DSS.

The MEK/ERK pathway is also associated with the MAP kinases (MAPKs), which may contribute to the visna virus-induced processes leading to neurodegenerative pathology. Treatment of visna virus-infected cells with PD 98059 (Fig. 9) , which had since long been recognized as a specific inhibitor of MAPK, 197, 198 abolished visna virus replication, 199 attesting as to the potential of PD 98059 to prevent the neuropathology of visna virus.

The replication of HCMV depends on a number of protein kinase pathways. Sorafenib is a multitargeted tyrosine kinase inhibitor registered for anticancer treatment (Nexavar R , Bayer and Onyx Pharmaceuticals). Through the MAPK signaling pathway, sorafenib may also interfere with the replication of HCMV. 200 Imatinib may suppress HCMV replication through inactivation of the platelet-derived growth factor-α receptor (PDGFR), which is a critical receptor required for HCMV infection. 201 Various protein kinase inhibitors containing a quinazoline moiety such as gefitinib (Iressa R , AstraZeneca and Teva) exert anti-HCMV activity in vitro and in vivo (gefitinib also inhibits the HCMV kinase UL97). 202 Furthermore, HCMV replication depends on the MEK/ERK pathway, and could therefore be suppressed by MEK inhibitors such as PD 98059. 203 In conclusion, MEK inhibitors may exhibit a broad-spectrum activity against a multitude of viruses, including influenza, herpes simplex, HIV and other retroviruses, dengue, corona, and HCMV. Although the antiviral effects could not be considered as highly specific, the advantage of MEK inhibitors, in view of their action targeted at a cellular process, is that they are unlikely to lead to the (rapid) emergence of drug resistance.

In the February 16, 2010, issue of the Proc Natl Acad Sci (USA) appeared a paper on a broad-spectrum antiviral agent LJ-001 targeting entry of envelope viruses, 204 followed in the October 5, 2010, issue of the same Journal by a remarkably similar antiviral activity of a structurally unrelated inhibitor dUY11. 205 LJ-001 is a rhodanine derivative and dUY11 is a rigid amphipathic fusion inhibitor (RAFI) derived from 2 -deoxyuridine (Fig. 10) . They both possess a rigid and planar hydrophobic moiety. With their hydrophobic moiety, LJ-001 and dUY11 would intercalate into the lipid bilayer of the viral envelope, thereby affecting the virus-cell fusion process. Both LJ-001 and dUY11 should, in principle, be active against all enveloped viruses. For two important human pathogens, HCV and HSV (-1 and -2), this activity was demonstrated, but for several others (i.e., yellow fever, dengue, Japanese encephalitis), this was not. In fact, the compounds should be compared side by side for their spectrum of activity. Admittedly, they should not easily lead to drug resistance development, but other issues should be further addressed, that is, in vivo activity and selectivity, biodistribution, drug formulation, r DE CLERCQ and pharmacodynamics, before their therapeutic value could be assessed. LJ-001 and dUY11 herald a new approach or strategy to combat enveloped virus infections, but the question can be raised whether they are druggable as well.

The author thanks Mrs. Christiane Callebaut for her proficient editorial assistance.

The discovery of antiviral agents: Ten different compounds, ten different stories

Antiviral drug discovery: Ten more compounds, and ten more stories (part B)

Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies and perspectives

Yet another ten stories on antiviral drug discovery (part D): Paradigms, paradoxes and paraductions

The next ten stories on antiviral drug discovery (part E): Advents, advances and adventures

In vitro selection of HCV replicons with reduced sensitivity to PSI-352938, a cyclicphosphate prodrug of β-d-2 -α-F-2 -β-C-methylguanosine

Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase

In vivo efficacy of N-methanocarbathymidine (N-MCT) against herpes simplex virus type 2 in neonatal guinea pigs

CMX001 (hexadecyloxypropyl cidofovir) antiviral activity against adenovirus in patients correlates with drug levels and viral sensitivity

Favipiravir (T-705) treatment of experimental arenaviral infection initiated after the onset of clinical disease

Combinatorial anti-arenaviral therapy with the small molecule SKI-1/S1P inhibitor PF-429242 and ribavirin

OBR-5-340-A novel pyrazolo-pyrimidine derivative with strong antiviral activity against Coxsackievirus B3 in vitro and in vivo

Identification and characterization of OBR-5-340 -a novel broad-spectrum anti-human rhinovirus (HRV) inhibitor

Mechanistic studies on a novel hydrophobic derivative of aglycoristocetin with potent and broad activity against influenza viruses

Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo

Rigid amphipathic fusion inhibitors (RAFIs) inhibit infectivity of enveloped viruses by targeting envelope lipids to prevent fusion with cellular membranes

Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2 -deoxy-2 -fluorocytidine

Design, synthesis, and antiviral activity of 2 -deoxy-2 -fluoro-2 -C-methylcytidine, a potent inhibitor of hepatitis C virus replication

Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2 -C-methylcytidine

The novel nucleoside analog R1479 (4 -azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture

Design, synthesis, and antiviral properties of 4 -substituted ribonucleosides as inhibitors of hepatitis C virus replication: The discovery of R1479

2 -deoxy-4 -azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2 -alpha-hydroxyl groups

The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4 -azidocytidine against hepatitis C virus replication: The discovery of 4 -azido-2 -deoxy-2 -fluorocytidine and 4 -azido-2 -dideoxy-2 ,2 -difluorocytidine

2 -deoxy-2 -α-fluoro-2 -β-C-methyl 3 ,5 -cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: Discovery of PSI-352938

An efficient and diastereoselective synthesis of PSI-6130: A clinically efficacious inhibitor of HCV NS5B polymerase

Mechanism of activation of beta-D-2 -deoxy-2 -fluoro-2 -C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase

Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2 -Deoxy-2 -fluoro-2 -C-methylcytidine (PSI-6130) and identification of a novel active 5 -triphosphate species

The mechanism of action of beta-D-2 -deoxy-2 -fluoro-2 -C-methylcytidine involves a second metabolic pathway leading to beta-D-2 -deoxy-2 -fluoro-2 -C-methyluridine 5 -triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase

PSI-7851, a pronucleotide of beta-D-2 -deoxy-2 -fluoro-2 -C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication

Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977

Discovery of a β-d-2 -deoxy-2 -α-fluoro-2 -β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus

Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661

Stereoselective synthesis of PSI-352938: A β-D-2 -deoxy-2 -α-fluoro-2 -β-C-methyl-3 ,5 -cyclic phosphate nucleotide prodrug for the treatment of HCV

Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2 -deoxy-2 -α-fluoro-2 -β-C-methylguanosine

INX-08189, a phosphoramidate prodrug of 6-O-methyl-2 -C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties

Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus

Methylenecyclopropane analogues of nucleosides as anti-herpes agents

Synthesis and antiviral activity of (Z)-and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: Second-generation methylenecyclopropane analogues of nucleosides

In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication

Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections

Pivotal role of animal models in the development of new therapies for cytomegalovirus infections

In search of effective anti-HHV-6 agents

L-valine ester of cyclopropavir: A new antiviral prodrug

Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility

Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir

Phosphorylation of antiviral and endogenous nucleotides to di-and triphosphates by guanosine monophosphate kinase

Phosphonate analogues of cyclopropavir phosphates and their E-isomers. Synthesis and antiviral activity

Nucleosides with a twist. Can fixed forms of sugar ring pucker influence biological activity in nucleosides and oligonucleotides

Metabolic pathways of N-methanocarbathymidine, a novel antiviral agent, in native and herpes simplex virus type 1 infected Vero cells

Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine

Dynamics of the antiviral activity of N-methanocarbathymidine against herpes simplex virus type 1 in cell culture

Experimental and structural evidence that herpes 1 kinase and cellular DNA polymerase(s) discriminate on the basis of sugar pucker

Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2 -deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R,5S)-and (-)-(1S,5R)-2-oxabicyclo

Activity and mechanism of action of Nmethanocarbathymidine against herpesvirus and orthopoxvirus infections

Cell line dependency for antiviral activity and in vivo efficacy of N-methanocarbathymidine against orthopoxvirus infections in mice

Efficacy of Nmethanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virus

Vaccinia virus lacking the deoxyuridine triphosphatase gene (F2L) replicates well in vitro and in vivo, but is hypersensitive to the antiviral drug (N)-methanocarbathymidine

Potent antiviral activity of north-methanocarbathymidine against Kaposi's sarcomaassociated herpesvirus

A greener enantioselective synthesis of the antiviral agent Northmethanocarbathymidine (N-MCT) from 2-deoxy-d-ribose

D-(+)-isomethanocarbathymidine: A high-affinity substrate for herpes simplex virus 1 thymidine kinase

The history of N-methanocarbathymidine: The investigation of a conformational concept leads to the discovery of a potent and selective nucleoside antiviral agent

Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art

Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies

Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection

Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro

Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir

Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection

Ether lipidester prodrugs of acyclic nucleoside phosphonates: Activity against adenovirus replication in vitro

Hexadecyloxypropylcidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model

Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001

Activities of various compounds against murine and primate polyomaviruses

Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression

Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro

1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells

Hexadecyloxypropyl-cidofovir (CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures

CMX001 (1-O-hexadecyloxypropylcidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes

Treatment of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia

Design and development of oral drugs for the prophylaxis and treatment of smallpox infection

Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir

Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir

Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model

Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies

Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics

Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model

Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001

A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus

Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: Pathogenesis, prophylaxis, and antiviral therapy

Efficacy of CMX001 as a post exposure antiviral in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans

Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans

Development of CMX001 for the treatment of poxvirus infections

Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro

Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine

Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir

vitro and in vivo activities of anti-influenza virus compound T-705

Mechanism of action of T-705 against influenza virus

Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells

T-705 (favipiravir) activity against lethal H5N1 influenza A viruses

Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice

In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses

Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice

T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections

Activity of T-1106 in a hamster model of yellow fever virus infection

Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106

Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents

Effect of T-705 treatment on western equine encephalitis in a mouse model

vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections

T-705 (favipiravir) inhibition of arenavirus replication in cell culture

Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin

Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models

Effective therapy with ribavirin

Ribavirin can be mutagenic for arenaviruses

Novel approaches in anti-arenaviral drug development

Arenaviruses and hantaviruses: From epidemiology and genomics to antivirals

Development of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog

Imidazo[2,1-b]thiazole carbohydrate derivatives: Synthesis and antiviral activity against Junin virus, agent of Argentine hemorrhagic fever

Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of Lassa virus

Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus

Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus

Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin

Cap binding and immune evasion revealed by Lassa nucleoprotein structure

Arenavirus reverse genetics: New approaches for the investigation of arenavirus biology and development of antiviral strategies

Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals

Aminopyrrolidineamide inhibitors of site-1 protease

Antiviral activity of a smallmolecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease

Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses

Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses

A specific interaction of small molecule entry inhibitors with the envelope glycoprotein complex of the Junín hemorrhagic fever arenavirus

pH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors

Identification of a broad-spectrum arenavirus entry inhibitor

Current status of anti-picornavirus therapies

Picornavirus inhibitors: Trifluoromethyl substitution provides a global protective effect against hepatic metabolism

Activity of pleconaril against enteroviruses

Treatment of potentially life-threatening enterovirus infections with pleconaril

FDA panel rejects common cold treatment

Kimberlin DW; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis

Pleconaril Respiratory Infection Study Group. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: Results of 2 double-blind, randomized, placebo-controlled trials

Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses

Selective inhibitors of picornavirus replication

Enteroviral meningitis: Natural history and outcome of pleconaril therapy

Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia

New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3

Synthesis and antiviral activity against Coxsackie virus B3 of some novel benzimidazole derivatives

A small interfering RNA targeting coxsackievirus B3 protects permissive HeLa cells from viral challenge

Combination of soluble coxsackievirus-adenovirus receptor and anti-coxsackievirus siRNAs exerts synergistic antiviral activity against coxsackievirus B3

Arylpurines as a novel class of enterovirus inhibitors

Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice

Inhibition of coxsackie B3 virus induced myocarditis in mice by 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile

The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis

Towards the design of combination therapy for the treatment of enterovirus infections

The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C

Potential use of antiviral agents in polio eradication

Picornavirus non-structural proteins as targets for new anti-virals with broad activity

Antiviral activity and constituent of Ardisia chinensis benth against coxsackie B3 virus

Antiviral activity and mode of action of caffeoylquinic acids from Schefflera heptaphylla (L.) Frodin

Anti-coxsackie virus B3 norsesquiterpenoids from the roots of Phyllanthus emblica

Antiviral triterpenoids from the medicinal plant Schefflera heptaphylla

In vivo and in vitro antiviral activities of calycosin-7-O-beta-D-glucopyranoside against coxsackie virus B3

Antiviral flavans from the leaves of Pithecellobium clypearia

Antiviral activity of substituted homoisoflavonoids on enteroviruses

Anti-human cytomegalovirus activity of constituents from Sasa albo-marginata (Kumazasa in Japan)

Anti-influenza virus activity by tricin, isolated from Sasa Albo-marginata in Japan

Increased bioavailability of tricin-amino acid derivatives via a prodrug approach

A specific inhibitor for tyrosine protein kinase from Pseudomonas

Genistein, a specific inhibitor of tyrosine-specific protein kinases

Genistein treatment of cells inhibits arenavirus infection

Arenavirus entry occurs through a cholesterol-dependent, non-caveolar, clathrin-mediated endocytic mechanism

Genistein, a general kinase inhibitor, as a potential antiviral for arenaviral hemorrhagic fever as described in the Pirital virus-Syrian golden hamster model

Antiviral activity of raoulic acid from Raoulia australis against Picornaviruses

Inhibition of poxvirus growth by Terameprocol, a methylated derivative of nordihydroguaiaretic acid

Nigericin is a potent inhibitor of the early stage of vaccinia virus replication

Modulation of glycosylation and transport of viral membrane glycoproteins by a sodium ionophore

Monensin and nigericin prevent the inhibition of host translation by poliovirus, without affecting p220 cleavage

Anti-influenza virus activity and structure-activity relationship of aglycoristocetin derivatives with cyclobutenedione carrying hydrophobic chains

Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

Antiviral effect of brassinosteroids against herpes virus and arenaviruses

Antiviral activity of brassinosteroids derivatives against measles virus in cell cultures

Antiviral mode of action of a synthetic brassinosteroid against Junin virus replication

Biyouyanagin A, an anti-HIV agent from Hypericum chinense L. var. salicifolium

Design, synthesis, and biological evaluation of a biyouyanagin compound library

Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer

Inhibition of influenza virus-induced NF-kappaB and Raf-MEK-ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo

MEK inhibition impairs influenza B virus propagation without emergence of resistant variants

Influenza virus-induced AP-1-dependent gene expression requires activation of the JNK signaling pathway

p38 mitogen-activated protein kinase and c-jun-NH2-terminal kinase regulate RANTES production by influenza virus-infected human bronchial epithelial cells

Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade

Modulation of HIV-1 infectivity by MAPK, a virion-associated kinase

Inhibition of CD3/CD28-mediated activation of the MEK/ERK signaling pathway represses replication of X4 but not R5 human immunodeficiency virus type 1 in peripheral blood CD4(+) T lymphocytes

Coxsackievirus B3 replication is reduced by inhibition of the extracellular signalregulated kinase (ERK) signaling pathway

Suppression of coronavirus replication by inhibition of the MEK signaling pathway

Distinct effects of knocking down MEK1 and MEK2 on replication of herpes simplex virus type 2

MEK-specific inhibitor U0126 blocks spread of Borna disease virus in cultured cells

he dengue virus envelope protein induced PAI-1 gene expression via MEK/ERK pathways

PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo

A synthetic inhibitor of the mitogenactivated protein kinase cascade

Visna virus-induced activation of MAPK is required for virus replication and correlates with virus-induced neuropathology

The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication

Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection

Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo

Extracellular signal-regulated kinase activity is sustained early during human cytomegalovirus infection

A broad-spectrum antiviral targeting entry of enveloped viruses

Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses

His scientific interests are in the antiviral chemotherapy field, and, in particular, the development of new antiviral agents for various viral infections, including herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV), human immunodeficiency virus (HIV), hepatitis B virus (HBV), human papilloma virus (HPV), and hepatitis C virus (HCV). He has (co)-discovered a number of antiviral drugs, currently used in the treatment of HSV infections (valaciclovir, Valtrex R , Zelitrex R )